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Abstract
We propose a novel multifactor dimensionality reduction method for epistasis detection in small or extended pedigrees,
FAM-MDR. It combines features of the Genome-wide Rapid Association using Mixed Model And Regression approach
(GRAMMAR) with Model-Based MDR (MB-MDR). We focus on continuous traits, although the method is general and can be
used for outcomes of any type, including binary and censored traits. When comparing FAM-MDR with Pedigree-based
Generalized MDR (PGMDR), which is a generalization of Multifactor Dimensionality Reduction (MDR) to continuous traits and
related individuals, FAM-MDR was found to outperform PGMDR in terms of power, in most of the considered simulated
scenarios. Additional simulations revealed that PGMDR does not appropriately deal with multiple testing and consequently
gives rise to overly optimistic results. FAM-MDR adequately deals with multiple testing in epistasis screens and is in contrast
rather conservative, by construction. Furthermore, simulations show that correcting for lower order (main) effects is of
utmost importance when claiming epistasis. As Type 2 Diabetes Mellitus (T2DM) is a complex phenotype likely influenced
by gene-gene interactions, we applied FAM-MDR to examine data on glucose area-under-the-curve (GAUC), an
endophenotype of T2DM for which multiple independent genetic associations have been observed, in the Amish Family
Diabetes Study (AFDS). This application reveals that FAM-MDR makes more efficient use of the available data than PGMDR
and can deal with multi-generational pedigrees more easily. In conclusion, we have validated FAM-MDR and compared it to
PGMDR, the current state-of-the-art MDR method for family data, using both simulations and a practical dataset. FAM-MDR
is found to outperform PGMDR in that it handles the multiple testing issue more correctly, has increased power, and
efficiently uses all available information.
Citation: Cattaert T, Urrea V, Naj AC, De Lobel L, De Wit V, et al. (2010) FAM-MDR: A Flexible Family-Based Multifactor Dimensionality Reduction Technique to
Detect Epistasis Using Related Individuals. PLoS ONE 5(4): e10304. doi:10.1371/journal.pone.0010304
Editor: Zolta´n Bochdanovits, VU University Medical Center and Center for Neurogenomics and Cognitive Research, VU University, Netherlands
Received January 12, 2010; Accepted March 1, 2010; Published April 22, 2010
Copyright:  2010 Cattaert et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The first author is a Postdoctoral Researcher of the Fonds de la Recherche Scientifique - FNRS. This work is also partially supported by grant MTM2008-
06747-C02-00 from the Ministerio de Ciencia y Tecnologia, Spain, by the Belgian Network BIOMAGNET (IAP P6/25), funded by the Interuniversity Attraction Poles
Programme, initiated by the Belgian State, Science Policy Office, and by the IST Programme of the European Community, under the PASCAL2 Network of
Excellence, IST-2007-216886. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: tom.cattaert@ulg.ac.be
Introduction
The International HapMap Project [1] was designed to create a
genome-wide database of human genetic variation, with the
expectation that these data would be useful for genetic association
studies of common diseases. This expectation has been fulfilled
with just the initial output of genome-wide association analyses,
identifying nearly 500 loci for over 80 common diseases and traits
[2,3]. Despite these successes, it has become clear that usually only
a small percentage of total genetic heritability estimates can be
explained by the identified loci. For instance, for inflammatory
bowel disease (IBD), 32 loci significantly impact disease but they
explain only 10% of disease risk and 20% of genetic risk [4]. This
may be attributed to the fact that recent findings show many types
of genetic associations for various traits, with subtle effects: non-
additive genetic effects, non-SNP polymorphisms, epigenetic
effects, but also gene-environment and gene-gene interactions [5].
The role of genetic interactions in explaining phenotypic variability
has been described in several publications [6,7,8,9,10,11,12,13,14,15].
Interactions may lead to inconsistent results from the masking of
associations, they can be suggestive of important pathogenic
mechanisms and may elucidate relevant opportunities for intervention
[16,17]. Epistasis, defined as the deviation from additivity of effects
observed at multiple genetic exposures [18,19], may also explain part
of the genetic heritability that is left unexplained for most complex
disorders [20]. These reasons have made epistasis an increasingly
accepted characteristic of the genetic architecture of common,
complex disorders [21,22,23,24].
One of the potential reasons for the small number of large-scale
genetic interaction studies performed in humans so far is that
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10304
although genetic interactions identified from model organisms
provide insight into biological processes, these biological processes
often lack sufficient overlap with other types of gene/protein
associations with traits of interest [25,26]. Also, the relatively low
success rate of large-scale epistasis searches to date may simply
reflect the limited ability to assess the many possible modes of
interaction, including pairwise interactions and threshold effects
[27] or inadequate solutions given to a difficult statistical challenge
[21]. In addition, subtle variation in allele frequency can either
introduce an interaction effect and likewise remove an interaction
effect from a particular dataset; this can make detection of epistasis
effects quite challenging [28]. Overviews of methods for epistasis
detection were given by Cordell [29,30] and by Onkamo and
Toivonen [31].
One non-parametric approach developed for epistasis analysis is
Multifactor Dimensionality Reduction [32,33,34] (MDR). Since its
conception, many methodological and applied papers have emerged
that build on or use MDR. To our knowledge, the current state-of-
the-art MDR-related method that can accommodate nuclear
families of any size and different types of outcome variables is the
recently proposed Pedigree-based Generalized MDR method [35]
(PGMDR) which generalizes the Generalized MDR method [36]
(GMDR) to family data. Its competitor, the MDR Pedigree
Disequilibrium Test [37] (MDR-PDT), is only suited for case-
control data and does not allow for covariate adjustments. Similar to
MDR, GMDR uses prediction accuracy measures for best model
selection. Significance assessment is based on random permutations.
To easily accommodate continuous traits and variable adjustments,
GMDR is based on scores of a (generalized) linear model. In the
special case of no covariates and a binary outcome it reduces to the
classical MDR. PGMDR first constructs a non-transmitted genotype
for every non-founder in the pedigree. When parental genotype
information is missing, PGMDR samples one realization of the
nontransmitted genotype from the conditional distribution given the
minimal sufficient statistic for the null hypothesis through an
algorithm that is modified from Rabinowitz and Laird [38]. Second,
the non-founders and the non-transmitted genotypes are analyzed by
the GMDR algorithm. Significance assessment is again based on
permutations. To maintain the correlation structure within the
families, families as a whole are used as permuting units and the
transmitted and non-transmitted sets in a whole family are randomly
shuffled. PGMDR software is available from the URL http://www.
healthsystem.virginia.edu/internet/addiction-genomics.
The need for new statistical methods to overcome some of the
remaining statistical hurdles in epistasis detection, has led to the
development of FAM-MDR. The method combines features of
the GRAMMAR approach [39] with features of Model-based
MDR [40] (MB-MDR).
In the Materials and Methods section, we introduce the FAM-
MDR algorithm and describe our extensive simulation study to
examine type I error and power of this approach. To examine the
application of FAM-MDR to determine epistasis in family studies
of a complex disease, we examined data on glucose area-under-
the-curve (GAUC), an endophenotype of Type 2 Diabetes
Mellitus (T2DM) for which multiple independent genetic
associations have been observed, in the extended pedigrees of
the Amish Family Diabetes Study [41] (AFDS). Subsequently, we
describe the power and type I error performance of FAM-MDR
in our simulations and application to AFDS, as well as a
comparative study between FAM-MDR and PGDMR, in the
Results section. Finally, the Discussion elaborates on the
significance of our results, and the relevance of its application
to finding gene-gene interactions in a complex disease like
T2DM.
Materials and Methods
The FAM-MDR algorithm
FAM-MDR is an acronym for FAMily Multifactor Dimension-
ality Reduction and is an adaptation to related individuals of the
Model-Based Multifactor Dimensionality Reduction method [40]
(MB-MDR) for epistasis detection with unrelated individuals. An
implementation of the FAM-MDR algorithm is available through
the URL www.statgen.be. The approach consists of two parts.
Part I: In order to deal with familial correlations between
observations, data are first analyzed using a polygenic model
Yi~mzGizei, ð1Þ
with i indexing individuals, G distributed MVN(0,Ws2poly) and e
distributed MVN(0,Is2env), representing the additive polygenic
and environmental effects respectively. The polygenic effect has
variance s2poly and is correlated within families, with correlation
matrix equal to the relationship matrix W. For the calculations we
use the polygenic function of R package GenABEL [39,42,43,44].
This package can be retrieved from the URL http://cran.
r-project.org/web/packages/GenABEL/index.html. The rela-
tionship matrix W can be derived either theoretically from the
pedigree structure, or can be estimated from the available genomic
data, in which case the genomic kinship is computed [45].
Genomic kinship is to be preferred when genome-wide data are
available, but of course in a candidate gene study genomic kinship
cannot be estimated in a reliable way and one will have to use
pedigree kinship [Aulchenko, GenABEL Tutorial]. The environ-
mental variance s2env is assumed to be the same for all individuals.
In addition, environmental effects are assumed to be independent
between individuals, whether belonging to different families or
within the same family, giving rise to an environmental variance-
covariance matrix Is2env (I : the identiy matrix of rank equal to the
number of individuals).
The residuals
e^i~Yi{(m^zG^i), ð2Þ
that have been derived from (1), are free from polygenic familial
correlation and can serve as new familial correlation-free traits to
be used in a genetic association analysis with measured genetic
markers. As a remark, m^ and G^i are estimates of mean m and
polygenic effect (or breeding value) Gi obtained by the
Expectation-Maximisation (EM) algorithm using the maximum
likelihood (ML) paradigm, hence maximizing the joint likelihood
of fixed effects and variance components [44]. In the GRAMMAR
approach of Aulchenko et al. [39], such a genetic association
analysis targets associations with single markers, one at a time, and
is fully parametric in nature. In contrast, in the FAM-MDR
approach, associations with multiple loci at once are evaluated.
Part II: Once the data have been prepared in Part I, FAM-
MDR proceeds with investigating the association between the
newly defined trait Ynew~e^i from Part I (in particular the
aforementioned residuals) and multi-locus measured genotypes,
using the potentially fully-parametric MB-MDRmethod (Figure 1).
It is justified to apply MB-MDR, that was developed for unrelated
individuals, to these residuals. Indeed, conditional on the observed
genotypes all the familial correlation has been accounted for.
Moreover, MB-MDR flexibly deals with different outcome types,
including those measured on a continuous scale. Like MDR, MB-
MDR reduces a high-dimensional interaction space to a 1-
FAM-MDR Epistasis Screening
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dimensional space, by assigning genetic effect size labels to multi-
locus genotypes, which will be further referred to as risk labels.
Key steps involved in a FAM-MDR Part II analysis are
summarized graphically in Figure 1. Because some characteristics
of MB-MDR have been altered in the FAM-MDR algorithm, we
summarize the key steps and properties of MB-MDR, and point out
changes we made to the initial MB-MDR algorithm. Throughout
this paper, for ease of exposition, we focus on two-locus models and
diallelic markers, although both MB-MDR and FAM-MDR are
applicable in principle to more general settings as well.
In MB-MDR step 1, for a selection of a pair of SNPs, each
genotype cell is tested against the eight others for association with
the trait. The cells that are found to be significantly associated with
the outcome, at a liberal threshold of 0.1, are then called high risk
(H ) or low risk (L) based on the position of the selected association
measure (e.g. T statistic or odds ratio) in the spectrum of all
possibilities. Those cells that are not significant at the threshold 0.1
are labeled as non-evidence cells (O). For a more detailed
discussion of the MB-MDR method we refer to Calle et al. [40]
and also to their technical report available from the URL http://
www.recercat.net/handle/2072/5001.
In step 2, two additional tests are performed for association with
the trait: testingH versus fL,Og and testing L versus fH,Og. This
gives rise to two Wald-type statistics of association, WH and WL,
that are either derived from a parametric or a non-parametric
testing approach.
In step 3, the significance of WH and WL is assessed through
permutations. This is different from the classical MB-MDR
implementation, but is an elegant way to compensate for the data
snooping in MB-MDR steps 1–2 and to correct for the otherwise
overly optimistic test results. Note that in the initial implementa-
tion of MB-MDR, depending on the number of combined cells in
either the high (low) risk cells pool, a different null distribution for
the corresponding Wald test statisticWH (WL) was derived. These
marginal null distributions were generated by simulating reference
data with similar characteristics. The multiple testing issue that
arises when considering different SNP pair combinations, is
tackled by MB-MDR [40] using BH-FDR (Benjamini-Hochberg
False Discovery Rate) methodology.[46] Because of the afore-
mentioned dependency on number of combined cells, and the
complexity of the significance assessment via a simulation-based
null distribution derivation in step 3, we chose to implement a
different approach. FAM-MDR therefore implements a permuta-
tion strategy by simply randomly permuting the familial
correlation-free residuals (2) obtained in FAM-MDR Part I. This
assumes a general null-hypothesis of no association between any of
the measured markers and trait (no main effects, no interaction
effects). This strategy does not depend on the number of combined
cells, nor on reference data.Although MB-MDR allows in
principle for multiple model selection, we have furthermore
restricted the approach to select only the best model, for the
purpose of comparison with PGMDR. In particular, we derive the
permutation null distribution of the maximum test statistic, i.e.
maximized over the two different tests (WH and WL) and all two-
SNP combinations j: maxH=L,j(WH,j ,WL,j) and recommend 1000
replications for doing so.
Moreover, we emphasize that corrections for main effects and
covariate adjustments are also possible in FAM-MDR and we
Figure 1. Summary of the steps involved in a FAM-MDR analysis. The figure shows the three steps of FAM-MDR Part II on one of the
simulated datasets for Model M27, p~0:25, g2~0:1 and h2~0:8, for the analysis without main effects correction.
doi:10.1371/journal.pone.0010304.g001
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choose to carry these out prior to association testing. Extending
the polygenic model (1) to a (two-locus) measured genotype (MG)
model [47] with the particular main effect/covariates present in
the model, has several advantages over adjusting while identifying
risk cells and/or testing for association between new one-
dimensional genetic constructs and the trait of interest. First, it
leads to more stable parametric estimations when adopting a
parametric regression approach in FAM-MDR Part II. Second, a
priori adjustment paves the way for a fully non-parametric
epistasis screening and thus faster MB-MDR runs on adjusted
residuals. Nevertheless, for the purpose of this paper, we will
continue to use the parametric linear model paradigm (in fact the
one-parameter Wald test is equivalent to the Student t-test) and
not the non-parametric alternative, the Wilcoxon rank sum test.
Third and most importantly, when residuals are free from
identified important main effects, the null hypotheses of no
association and of no epistasis become equivalent and the
permutation procedure is a correct procedure for claiming
epistasis, i.e. association above and beyond the main effects
corrected for in FAM-MDR Part I.
Finally, a note on how FAM-MDR handles missing data. For
missing genotypes, FAM-MDR uses the available cases (AC)
paradigm. In other words, if a particular pair is considered, only
individuals with complete data for this pair are included in the
analysis, while individuals with missing data for one or two SNPs
involved are not considered. Individuals with missing trait values
are used in FAM-MDR Part I only when they are useful for
deriving the relationship matrix, but never for the polygenic
calculations themselves. Indeed, if the number of markers is small,
the theoretical relationship matrix is used and the complete
pedigree is needed for calculating this in a correct way. When the
number of markers is large, FAM-MDR relies on the genomic
kinship matrix and there is no need to keep individuals with
missing trait values in the analysis. Note that since we are not using
the individuals with missing trait values for the polygenic
calculations, we essentially are performing a complete case (CC)
analysis. Also, when correcting for main effects/covariates - since
we only use those individuals with complete data on the main
effects/covariates that are regressed out in Part I, we are again
following the CC paradigm. In Part II, FAM-MDR obviously does
not use missing new trait values, whether these are due to missing
trait values or missing main effects/covariates adjusted for.
Missing new trait values are also not included in the permutation
procedure. It is good to recall that both AC and CC are valid
under a missing completely at random (MCAR) missingness
process [48].
Simulation study
We simulated data consisting of 250 nuclear families, with the
number of children drawn from a multinomial distribution with
probabilities 1/4 to have one child (hence a trio), 1/2 to have two
children, and 1/4 to have three children. On average, this gave
rise to 1000 individuals. We assumed that no data were missing. In
other words, complete information on genotypes at all loci and
complete information on phenotypes were available.
To generate genotypes for these individuals, we first generated ten
diallelic markers: SNPl ,l~1,:::,10, in linkage equilibrium. In
addition, we assumed Hardy-Weinberg equilibrium for every
generated marker. In other words, the genotype frequencies can be
determined from the allele frequencies as follows: fl0~(1{pl)
2,
fl1~2pl(1{pl), and fl2~p
2
l . The allele frequencies of a non-
functional SNP, SNPj was fixed at pj~0:1z(j{3)0:05, j~3,:::,10,
whereas the allele frequencies of the functional SNP pair
SNP1,SNP2ð Þ were taken to be equal, and varied as
(p1,p2)~(p,p), p[f0:1,0:25,0:5g. Parental genotypes were then
drawn according to the population genotype frequencies above.
Children’s genotypes were assumed to follow Mendelian inheritance
patterns.
Assuming the presence of additive polygenes and a residual
environmental effect, phenotypes were simulated according to the
(two-locus) MG model
YI~mk1i ,k2izGizei, ð3Þ
with the notations of Expression (1) before. Note the difference of
the fixed effect mean term, m in (1), which is replaced by mk1i ,k2i in
(3). Here, kli refers to the minor allele count kl[f0,1,2g for
individual i and mk1k2 represents the mean trait values according to
the functional SNP pair. Trait values per family were then sampled
from a multivariate normal distribution, with as components of the
mean vector the trait mean values mk1i ,k2i corresponding to the two-
locus genotypes that the individuals constituting the family belong
to, and as variance-covariance matrix the part of Ws2polyzIs
2
env
pertaining to that family. In what follows, we explain in detail the
simulation parameter settings of our choice.
First, we notice that the population two-locus model variance
s2loci is computed as a weighted sum of squares, with weights
determined by population genotype frequencies (exploiting no LD
between the markers)
s2loci~
X
k1
X
k2
f1k1 f2k2 (mk1k2{m
::)2, ð4Þ
in which the overall mean m:: is computed as
m::~
X
k1
X
k2
f1k1 f2k2mk1k2 : ð5Þ
In a similar way, the single-locus means and variances are
respectively given by
mk1
:~
X
k2
f2k2mk1k2 , ð6Þ
m:k2~
X
k1
f1k1mk1k2 , ð7Þ
and
s21~
X
k1
f1k1 (mk1
:{m::)2, ð8Þ
s22~
X
k2
f2k2 (m:k2{m
::)2: ð9Þ
Hence, since p1~p2, and therefore also s
2
1~s
2
2, the epistatic
variance s2epi, defined as the part of the two-locus model variance
that is not explained by the contributing loci separately, is given in
our simulation settings by s2epi~s
2
loci{2s
2
1. Different contributions
to the two-locus model variance of the epistatic variance s2epi or the
main effects model variance will be important in interpreting
simulation results.
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The total phenotypic variance, which is given by
s2tot~s
2
locizs
2
polyzs
2
env, ð10Þ
was kept fixed at s2tot~1 for all simulations. The total heritability
h2 of the trait, defined as
h2~
s2locizs
2
poly
s2tot
, ð11Þ
was taken to be h2[f0:3,0:5,0:8g. The proportion g2 of the total
variance s2tot explained by the total two-locus model variance s
2
loci,
g2~
s2loci
s2tot
, ð12Þ
varied as g2[f0,0:01,0:02,0:03,0:05,0:1g. Because of the afore-
mentioned assumptions, and the definitions for h2 and g2, we have
s2loci~g
2, s2poly~(h
2{g2), and s2env~(1{h
2). Hence, given h2
and g2, the three variance contributions are completely deter-
mined. Since only 10 SNPs were considered in all scenarios, the
relationship matrix was derived from the nuclear family actual
relationships.
Second, the fixed mean part in (3) needs to be determined. For
this, we consider two two-locus models, M27 and M170, of Li and
Reich [49,50]. The key feature of Model M27 is that phenotypic
means increase when for both loci at least one variant allele is
present. In contrast, in Model M170 increased phenotypic values
occur only when at one (and only one) locus a heterozygous
genotype is observed. Explicitly, Models M27 and M170 are
respectively determined by
mM27k1ik2i
!
0 0 0
0 1 1
0 1 1
0
B@
1
CA, ð13Þ
And
mM170k1ik2i
!
0 1 0
1 0 1
0 1 0
0
B@
1
CA: ð14Þ
It is important to realize that the two-locus variance s2loci, can be
computed from the genotype-specific means mk1k2 above and the
minor allele frequency p. Hence, since the total trait variance s2tot
was set to 1, and since particular values for the two-locus model
heritability g2 were also pre-specified, the means in (13) and (14)
are actually proportional to the specifications to the right of the
corresponding expression.
To enhance the interpretation of future simulation results, it is
instructive to more closely look into the decomposition of the two-
locus model variances for Models M27 and M170 into main effects
and epistatic variance (Table 1). We observe that for Model M27
the contribution of main effects becomes increasingly important
with increasing p, whereas for Model M170 the reverse is true,
leading to a pure epistasis scenario for p~0:5.
The two different genetic two-locus models (M27 and M170),
three possible minor allele frequencies p of the causal SNP pair, 5
different non-zero values for g2 and three different values for the
total heritability h2, lead to a total of 90 simulation settings. For
each of these settings 100 data sets were simulated.
Under the general null hypothesis of no association with the
trait (no main effects, nor two-way interaction effects), in
particular, g2(~s2loci)~0, the different genetic models M27 and
M170 are irrelevant. The three possible choices for the minor
allele frequency p of the causal SNP pair, and the three possible
values for h2 result in nine different general null hypothesis
simulation settings. For each of these settings we generated 400
datasets.
Because we are primarily interested in detecting epistasis effects
above and beyond main effects, when these main effects are
present, we also generated a different type of null data, under the
null hypothesis of no epistasis, but main effects. Hence, g2w0 and
mmaink1k2
~mk1
:zm:k2 , ð15Þ
effectively reducing the two-locus variance to 2s21vs2loci, while
increasing the polygenic variance. For each of the 75 simulation
settings, we again generated 100 datasets.
To reduce the computational burden of our extensive
simulation study, we adopted a sequential approach [51] during
the permutation step of FAM-MDR (FAM-MDR Part II step 3).
We carried out the permutation calculations in batches of 100, and
each time evaluated a go or no go to continue or not, setting the
maximum number of permutations to 1000. To this end, we
determined the binomial (1{c)100% confidence interval of the
significance level a at the current number of permutations, with
a~0:05 and c~0:05. If the current estimate of the permutation p-
value fell outside this confidence interval, the permutation
procedure terminated and a definite conclusion about significance
or non-significance was made. If the current estimate of the
permutation p-value fell inside the confidence interval, no
decisions were made about significance and an additional batch
of 100 permutations were performed. A drawback of this
sequential approach is that no accurate estimate of the
permutation p-value is output. Hence, whereas it serves its
purpose for simulation studies, it is less well suited for real data
applications.
Only to enhance an honest comparison of simulations results
with PGMDR, we also introduced a liberal version of FAM-MDR,
referred to as FAM-MDR*. In contrast to PGMDR [35] and
GMDR [36], for which the permutation null distribution is only
derived with respect to the actual SNP pair identified by the initial
epistasis screening, FAM-MDR screens all SNP pairs in a
permuted dataset. By doing so, FAM-MDR assesses significance
of the best SNP-pair, while appropriately correcting for multiple
testing. FAM-MDR* assesses marginal significance of the best
Table 1. Relative importance of main effects and epistatic
variances for different two-locus models.
M27 M170
p Main Epist. Main Epist.
0.10 0.16 0.68 0.29 0.42
0.25 0.30 0.39 0.06 0.88
0.50 0.43 0.14 0.00 1.00
Abbreviations: Main = ratio s21

s2loci of each of the main effects variances s
2
1 to
the two-locus variance s2loci , Epist. = ratio s
2
epi
.
s2loci of the epistatic variance s
2
epi
to the two-locus variance s2loci .
doi:10.1371/journal.pone.0010304.t001
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model by computing the empirical marginal p-value of the pair
found. This was done by only maximizing over the two test
statistics WH and WL, and by restricting attention to the specific
pair jfound identified via the initial epistasis data analysis:
maxH=L WH,jfound ,WL,jfound
 
. Although FAM-MDR* is less com-
putationally intensive, it leads to overly optimistic results, and
increased false positive rates, just like PGMDR. In line with
PGMDR [35], 1000 permuations were used to estimate
significance, hence no sequential approach is adopted.
Finally, we analyzed all simulated datasets with both FAM-
MDR and FAM-MDR*. We applied PGMDR to all simulation
settings with non-zero epistasis, and to 200 (out of 400) generated
data sets for each of the simulations settings under the general null
hypothesis of no association. Every analysis is carried out once
with and without main effects correction. The former involves
adjusting for SNP1 and SNP2 by assuming a co-dominant mode of
inheritance. The analysis with correction for main effects leads to
the detection of two-locus effects beyond co-dominant main
effects. The analysis without correction for main effects leads to the
detection of a two-locus model but without giving a clue about
whether this model is genuinely indicative for epistasis or for main
effects, or for both. In PGMDR analyses, and when correcting for
SNP1 and SNP2 main effects, we created two dummy variables for
each of the causal SNPs and submitted them as covariates to the
PGMDR software.
Amish Family Diabetes Study
The Amish Family Diabetes Study [41] (AFDS) is a study to
identify the genetic determinants of type 2 diabetes and related
traits in multi-generational extended pedigrees from the Old
Order Amish (OOA) community, a genetically-isolated group in
Lancaster County, Pennsylvania. For this analysis, we examined
genotype data for 25 SNPs in five diabetes candidate genes,
adipocnectin receptors 1 and 2 (ADIPOR1, ADIPOR2), adiponectin
(APM1, also known as ADIPOQ), calsequestrin 1 (CASQ1), and
hepatocyte nuclear factor 4A (HNF4A), in 1427 individuals from a
single large multi-generational pedigree subdivided into 243
independent families for analysis and 25 SNPs. In previous
analyses in the AFDS [52,53,54,55], rs1884614 in HNF4A [52],
rs2275703 and rs617698 in CASQ1 [54], and rs1029629 in
ADIPOR2 [53] were found to be significantly associated with the
continuous trait Glucose area under curve (GAUC). The latter was
estimated using the trapezoid method from glucose levels taken at
30-minute intervals in a three-hour oral glucose tolerance test
(OGTT) administered to all AFDS subjects without a prior history
of diabetes [56]. We examined log (GAUC) as our continuous
trait of interest, in non-diabetic individuals with GAUC measure-
ment available, setting GAUC to missing for diabetics and
individuals with unknown diabetes status because for diabetics the
GAUC measurement is expected to be biased. We took the natural
logarithm of GAUC because the Shapiro-Wilk test strongly
rejected normality of the residuals of the polygenic model in an
analysis on GAUC itself, whereas it did not so in an analysis on
log (GAUC). After removing Mendelian errors as found by FBAT
(downloadable from URL http://www.biostat.harvard.edu/
,fbat/default.html), we used the check.marker function of R
package GenABEL on these 725 non-diabetics with GAUC
measurement available. We put extr.call and extr.perid.call equal
to 0.25, so that markers and individuals with call rates below 0.25
are removed prior to main analysis. For the main analysis we put
callrate and perid.call to 0.9 so we discard iteratively markers and
individuals with call rates below 0.9. We discarded four SNPs,
rs6666089 and rs1342387 in ADIPOR1, and rs617599 and
rs1186694 in CASQ1, due to low callrates. All markers had minor
allele frequencies above 1%. We also discarded 105 individuals
due to low callrates, by putting their GAUC measurement to
missing. All analyses are based on the remaining 21 markers and
620 individuals.
In order to derive the correct relationships between the 620
individuals of interest, FAM-MDR also makes use of the
remaining 807 individuals without GAUC measurement available
and – in order to recognize relationships between offspring – of
additional parental information (804 parents, without genotype
nor phenotype information). Hence, ‘‘information’’ of 2231
individuals was exploited by FAM-MDR. The 620 individuals of
interest correspond to 136 independent families. Of these, 75
consisted of unrelated single individuals with no genotyped first-
degree relatives, 33 were nuclear families (comprising 51 of the
620 individuals or interest), and 28 were multi-generational
families. However, these 28 families included 471 or 76% of the
620 individuals.
Because the present PGMDR implementation cannot deal with
large multi-generational (non-nuclear) pedigrees, and only for
reasons of comparison between PGMDR and FAM-MDR, we
split multi-generational pedigrees into nuclear families. In the
resulting set of nuclear pedigrees, 344 individuals were represented
twice, most often as offspring in one pedigree and parents in
another. The net result of the splitting process was a set of 584
non-independent nuclear families, comprising 2575 ( = 2231+344)
individuals. Of the 620 individuals with GAUC measurement
available, 161 were represented twice, resulting in a total of 781
individuals of interest to us, in 363 non-independent families. Of
these families, 255 were part of the 28 extended pedigrees, while
the remaining 108 were mutually independent. There is clearly a
need to account for the lack of independence between these
nuclear families. Unfortunately, the PGMDR software is unable to
do so. Solely for reasons of comparison, FAM-MDR was applied
to the split-pedigree data, as well as to the original multi-
generational family data.
Analyses were carried out with and without correction for the
main effects of rs1884614 in HNF4A, rs2275703 and rs617698 in
CASQ1, and rs1029629 in ADIPOR2. They were regressed out in
FAM-MDR Part I, or entered as covariates in PGMDR, using co-
dominant coding. P-values were based on 1000 permutations for
both PGMDR and FAM-MDR, hence no stopping rules were
used. The significance level was set at a~0:05.
Without main effects correction, FAM-MDR on the original
data uses all 620 individuals with GAUC value available. When
correcting for main effects, missing genotype information
contributes to an increased missingness rate for the new trait
values. Here only 572 or 92% of the 620 individuals have non-
missing new trait values. On the split-pedigree data, 781
individuals are available for FAM-MDR without main effects
correction, and 726 for FAM-MDR with main effects correction.
Note that this is in fact an artificial increase in sample size of 26%
and 27% respectively. In contrast to FAM-MDR, PGMDR works
with the transmitted genotype information. Of the 620 individuals
with a GAUC value available, the 75 unrelated individuals
(singletons) obviously did not have parental information available,
giving rise to 545 individuals eligible for PGMDR analysis.
Furthermore, whenever genotypes for any SNP are completely
missing for a family, PGMDR simply discards the whole family
from the entire epistasis screening. As a result, PGMDR uses only
537 individuals in an analysis without correction for main effects,
and 501 individuals in an analysis with main effects correction,
amounting to reductions of 13% and 12% compared to the
corresponding FAM-MDR analyses. Consequently, PGMDR does
not use all information available.
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Results
Simulation study
As a quality check on the simulated data, we first assessed the
values of the Hardy Weinberg and Linkage Disequilibrium
correlation coefficients rHW and rLD, in the parents only. All
correlation coefficients were consistent with the theoretical value of
0. More specifically, we observed that for all considered simulation
settings the 95% confidence intervals of the correlation coefficients
rHW and rLD lied within the range ½{0:11,0:11. We have also fit
a full MG model with a covariate coding for the exact
dichotomization that is behind our models. In this way we were
able to consistently estimate the effect sizes, showing that our data
are indeed behaving in the way we intended.
We first considered simulation results under the general null
hypothesis of no association (no main effects, no two-order
interactions). Empirical type I error rates were defined as the
number of times the selected best 2-locus model was assessed
significant, divided by the number of simulations. From Table 2,
we notice that FAM-MDR typically gives smaller empirical type I
error rates than the nominal type I error rate of a~0:05. In other
words, FAM-MDR has the tendency to be conservative. In
contrast, FAM-MDR* and PGMDR are much too liberal. The
latter is not surprising, since both FAM-MDR* and PGMDR
completely ignore the multiple testing issue. These results are
confirmed by Figure 2, showing the Probability-Probability (PP)
plots of the p-value distributions under the general null hypothesis
of no association for p~0:5 and h2~0:3. The PP-plots are based
on 100 datasets and 1000 permutations, without stopping rule to
obtain exact p-values. The plots show the expected ordered p-
values (i{1=2)=100 on the horizontal axis and the observed
ordered p-values p(i) on the vertical axis. By consequence, a
certain theoretical significance level on the vertical axis can be
related to a particular empirical type I error rate on the horizontal
axis. For FAM-MDR (panel A) the curve lies slightly above the
diagonal, indicating a rather conservative approach. For FAM-
MDR* (panel B) and PGMDR (panel C) the curve lies far below
the diagonal, pointing to an extremely liberal approach. Only
when performing the PGMDR on simulated data with two
functional (and no non-functional!) SNPs (panel D), the PP-plot
looks acceptable, although rather conservative as well.
Second, we considered the simulated null data under the null
hypothesis of no epistasis, in the presence of main effects. If under
this null a two-locus model is identified (that is, a two-locus model
is assessed significant), then a type I error has been made with
regard to the null hypothesis of no interaction, and the significant
result may be largely driven by main effects. Type I error rates for
a variety of scenarios are given in Table 3. The analyses
correcting for main effects have reasonable type I error rates,
although also they tend to be rather conservative. This holds for
both Models M27 and M170. The analyses not correcting for
main effects have the tendency to give rise to an increased
number of false positives. This increase is sometimes dramatic,
going even up to 1. The estimated type I error rates point towards
the importance of using analysis techniques that are able to
appropriately account for important lower order effects. The
observation that type I error rates increase with increasing values
of g2, is to be expected. Indeed, when g2 increases, also the main
effects variance increases. Moreover, as the minor allele
frequency p of the functional SNPs increases, type I error rates
increase for Model M27 but decrease for Model M170. This can
be explained by the relative importance of the main effects with
varying p for the different models (Table 1). Note that for Model
M170 and p~0:5 no results are stated because this situation
corresponds to a pure epistasis scenario. Figure S1 (Supporting
Information) gives a graphical illustration of the liberal type I
error rates. Panel D shows results for the analysis not correcting
for main effects on data generated under the null of no epistasis
for model M27 and the extreme g2~0:1. We observe that the
probability-probability plot in this setting is perfectly horizontal at
height 0. This extreme case corresponds to the fact that the type I
error rate is 1 for this situation.
Third, we considered simulated data under the alternative
hypothesis of epistasis (possibly in the presence of main effects).
For every simulation setting, empirical power was defined as the
number of times the correct pair SNP1,SNP2ð Þ was selected and
declared significant, divided by the number of simulated data sets.
For PGMDR, it happened that two or even three models were
reported by the software. In this event, the reported models had
exactly the same cross-validation consistency, and we selected the
model with the lowest permutation p-value. In the rare event that
also the reported permutation p-values were tied, we made a random
choice, except when the true functional model was among the
reported results. In the latter case, we always selected the true
functional model among the tied results. Table 4 gives an overview of
the simulation results under a variety of alternative hypotheses.
Figure 3 displays our findings graphically for h2~0:3. In the
Supporting Information, we give additional power graphs for
h2~0:5 and h2~0:8, for Model M27 (Figure S2) and Model
M170 (Figure S3), but these do not fundamentally differ from those
for h2~0:3. In general, FAM-MDR has systematically higher power
than PGMDR, even with appropriate correction for multiple testing.
Note that FAM-MDR* may well be the most powerful approach
but, like PGMDR, it does not appropriately handle multiple testing
problems. There are a few exceptions to these general observations.
However, in these exceptional cases, the power gain of PGMDR is
always very small, and the apparent better performance of PGMDR
can just as well be due to sampling variability. Indeed, the standard
error of a binomial proportion is about 0.05 for 100 simulated
datasets. The results of Table 4 show that power estimates increase
with increasing two-locus heritability g2.
Our simulation data does not show a systematic trend with
increasing total heritability h2. When correcting for main effects,
Table 2. Type I error rates under the general null hypothesis
of no association.
Corr. No C.
p h2 F F* PG F F* PG
0.1 0.3 0.0200 0.5700 0.4450 0.0250 0.6725 0.4700
0.5 0.0275 0.4550 0.5300 0.0300 0.5650 0.5300
0.8 0.0100 0.4825 0.5950 0.0175 0.5450 0.4900
0.25 0.3 0.0275 0.5650 0.4750 0.0250 0.6650 0.5250
0.5 0.0225 0.5325 0.4750 0.0200 0.6025 0.5200
0.8 0.0175 0.5125 0.4800 0.0150 0.6000 0.4800
0.3 0.3 0.0275 0.5525 0.5400 0.0275 0.6475 0.5600
0.5 0.0175 0.5625 0.5350 0.0325 0.6300 0.5600
0.8 0.0100 0.4900 0.4750 0.0100 0.5250 0.5100
Results are based on 400 simulated datasets for each setting for FAM-MDR and
FAM-MDR* and 200 datasets for PGMDR. As an aid to interpretation the type I
error rates §0:1 are indicated in bold. Abbreviations: Corr. =with main effects
correction, No C. =without main effects correction, F = FAM-MDR,
F* = FAM-MDR*, PG = PGMDR.
doi:10.1371/journal.pone.0010304.t002
FAM-MDR Epistasis Screening
PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10304
the power decreases with minor allele frequency p for model M27.
The reverse is observed for Model M170. This can be explained
by the proportion s2epi
.
s2loci of the epistatic variance to the total
two-locus variance, varying with p for the two models in a different
way, as given in Table 1. For example, for Model M27 and
p~0:5, in which case the ratio s2epi
.
s2loci is only 0.14, the power is
very low. For the analysis without correction for main effects,
power is less dependent on p and high power levels are probably
indicative for excessive type I error rates due to lower order effects
signaling through to the higher order models. Correcting for main
effects generally gives rise to lower power estimates than not
correcting for main effects (Table 4 and Figure 3). There are two
reasons for this. First, the epistatic variance s2epi (targeted by an
analysis with correction for main effects) is generally smaller than
the total two-locus variance s2loci (which is the focus of an analysis
without correction for main effects). Consequently, larger sample
Figure 2. Probability-probability plots based on 100 replicates under the complete null hypothesis of no association. Data are
generated with no main effects and no two-way interaction effects, with p~0:5 and h2~0:3. Analyses are performed without correction for main
effects. The first three panels show results of FAM-MDR (A), FAM-MDR* (B) and PGMDR (C) for the usual situation study considering 10 SNPs. The final
panel (D) shows PGMDR results when only 2 SNPs are considered. The straight lines indicate the theoretical probability-probability curve (light blue)
and the 5% significance level (dark blue).
doi:10.1371/journal.pone.0010304.g002
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sizes are needed to enable epistasis detection. Second, there is
some efficiency loss because every main effect corrected for
contributes two degrees of freedom (as main effects were coded as
co-dominant effects). That there is a price to pay for estimating
additional parameters can most clearly be deduced from the
results for Model M170 and p~0:5 (pure epistasis), for which we
still observe the reduction in power for the analysis with main
effects corrections over an uncorrected analysis. Another example
is that for Model M27 with p~0:1 the analyses without main
effects corrections g2~0:02 have higher power than the corrected
analyses for g2~0:05, although in the first case s2loci~0:2 and in
the second case s2epi~0:0204.
Amish Family Diabetes Study
Table 5 shows the results of epistasis screening with FAM-
MDR and PGMDR on the split pedigree data, and of FAM-
MDR on the multi-generational pedigree data, both with and
without correction for co-dominant main effects of rs1884614 in
HNF4A, rs2275703 and rs617698 in CASQ1 and rs1029629 in
ADIPOR2. Without correction for main effects, FAM-MDR on
the cut-pedigree data finds a significant two-locus model
involving rs2275703 in CASQ1 and rs1501299 in APM1. When
performing a main effects correction, the same best interaction
model is identified. However, the interaction is significant only
at the 10% significance level, suggesting that the two-locus
model is to some extent driven by the main effect of rs2275703.
PGMDR without main effects correction does not lead to a
significant interaction. With correction for main effects,
PGMDR reports a different near-significant two-locus model
involving rs2275703 in CASQ1 and rs1028583 in HNF4A. FAM-
MDR on the original data, with or without correction for main
effects, does not yield any significant two-locus models. Possible
explanations for these contradicting results are reviewed in the
Discussion section.
Discussion
The objectives of this paper were to introduce a new family-
based and flexible epistasis detection analysis method, FAM-
MDR, which is based on multifactor dimensionality reduction of
multi-locus genotypes, and to compare it to the current state-of-the
art MDR methodology for families, PGMDR. Although principles
of the initial MDR approach are adopted in FAM-MDR, there are
some clear differences. These include an alternative way to identify
risk categories associated with multi-locus genotypes, the flexibility
to use any outcome type, the possibility to correct for lower order
effects, covariates or confounding factors, the possibility to assess
significance of multiple higher-order interaction models. Since
model selection is not based on evaluating prediction accuracy but
on testing associations, FAM-MDR does not involve computa-
tionally intensive cross-validation steps.
FAM-MDR consists of two parts. In part I, residuals are derived
from a polygenic model, removing additive polygenic effects and
possibly important lower-order effects or confounding factors.
These residuals are subsequently considered as new traits for the
second part of FAM-MDR. In Part II, the familial correlation-free
residuals are submitted to the MB-MDR algorithm and either the
best model (considered in this manuscript), or multiple epistasis
models are checked for their significance. In contrary to first
implementations of the MB-MDR algorithm, no simulation-based
null distributions are derived to assess significance, but a
permutation-based strategy is adopted. Under the assumption of
familial correlation-free traits in FAM-MDR Part II, permutation-
based p-values for the best model can easily be derived by
randomly permuting the traits. This is in contrast to PGMDR’s
implementation of a permutation strategy in that for PGDMR
families are considered as the permutation units.
The method of removing familial-correlation structure is not new.
The GRAMMAR approach of Aulchenko et al. [39] and Amin et al.
Table 3. Type I error rates of FAM-MDR under the null hypothesis of no epistasis.
M27 M170
p=0.1 p=0.25 p=0.5 p=0.1 p=0.25
g2 h2 Corr. No C. Corr. No C. Corr. No C. Corr. No C. Corr. No C.
0.01 0.3 0.05 0.09 0.02 0.07 0.01 0.21 0.03 0.16 0.01 0.01
0.5 0.00 0.01 0.01 0.03 0.03 0.16 0.00 0.03 0.00 0.03
0.8 0.03 0.04 0.01 0.05 0.02 0.06 0.01 0.02 0.00 0.01
0.02 0.3 0.01 0.10 0.03 0.23 0.03 0.40 0.03 0.22 0.07 0.07
0.5 0.02 0.06 0.00 0.17 0.03 0.35 0.03 0.19 0.03 0.03
0.8 0.00 0.03 0.01 0.12 0.03 0.35 0.01 0.20 0.01 0.00
0.03 0.3 0.03 0.21 0.01 0.41 0.01 0.66 0.01 0.40 0.05 0.08
0.5 0.02 0.16 0.02 0.38 0.01 0.68 0.02 0.33 0.00 0.04
0.8 0.01 0.09 0.01 0.40 0.02 0.72 0.01 0.32 0.02 0.03
0.05 0.3 0.03 0.42 0.02 0.75 0.02 0.94 0.01 0.79 0.06 0.11
0.5 0.02 0.26 0.01 0.82 0.02 0.96 0.00 0.82 0.02 0.13
0.8 0.01 0.18 0.02 0.72 0.01 0.96 0.01 0.63 0.01 0.09
0.1 0.3 0.03 0.96 0.02 1.00 0.02 1.00 0.00 1.00 0.01 0.29
0.5 0.03 0.84 0.01 0.99 0.01 1.00 0.03 0.99 0.01 0.34
0.8 0.00 0.67 0.02 0.99 0.00 1.00 0.03 1.00 0.01 0.37
Results are based on 100 simulated datasets for each setting. As an aid to interpretation the type I error rates §0:1 are indicated in bold. Abbreviations: Corr. =with
main effects correction, No C. =without main effects correction.
doi:10.1371/journal.pone.0010304.t003
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Figure 3. Power of FAM-MDR and PGMDR based on 100 replicates, with h2~0:3. The different panels show results for M27 (A) and M170 (B).
Abbreviations: Corr. =with main effects correction, No Corr. =without main effects correction.
doi:10.1371/journal.pone.0010304.g003
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Table 4. Power of FAM-MDR, FAM-MDR* and PGMDR.
M27 M170
Corr. No C. Corr. No C.
p g2 h2 F F* PG F F* PG F F* PG F F* PG
0.1 0.01 0.3 0.03 0.17 0.03 0.19 0.40 0.01 0.01 0.10 0.01 0.16 0.36 0.06
0.5 0.01 0.12 0.03 0.13 0.47 0.00 0.00 0.06 0.00 0.13 0.41 0.10
0.8 0.02 0.19 0.00 0.09 0.42 0.01 0.01 0.14 0.00 0.08 0.35 0.04
0.02 0.3 0.05 0.30 0.03 0.46 0.67 0.01 0.01 0.20 0.03 0.58 0.79 0.19
0.5 0.05 0.38 0.02 0.43 0.68 0.01 0.03 0.20 0.01 0.49 0.71 0.01
0.8 0.06 0.49 0.01 0.53 0.82 0.01 0.05 0.26 0.02 0.42 0.73 0.23
0.03 0.3 0.12 0.67 0.05 0.83 0.91 0.01 0.05 0.30 0.04 0.78 0.91 0.33
0.5 0.24 0.72 0.04 0.87 0.97 0.00 0.11 0.43 0.00 0.90 0.98 0.31
0.8 0.32 0.73 0.02 0.73 0.94 0.01 0.15 0.48 0.01 0.93 0.99 0.32
0.05 0.3 0.40 0.90 0.11 0.96 0.99 0.02 0.25 0.73 0.05 1.00 1.00 0.53
0.5 0.48 0.93 0.10 0.98 0.99 0.02 0.30 0.75 0.03 1.00 1.00 0.55
0.8 0.67 0.95 0.09 0.98 1.00 0.01 0.53 0.90 0.06 1.00 1.00 0.61
0.1 0.3 0.98 1.00 0.40 0.98 0.98 0.02 0.69 0.94 0.17 1.00 1.00 0.89
0.5 0.96 1.00 0.32 1.00 1.00 0.03 0.80 0.97 0.21 1.00 1.00 0.95
0.8 0.95 1.00 0.28 1.00 1.00 0.00 0.81 0.97 0.13 1.00 1.00 0.94
0.25 0.01 0.3 0.01 0.06 0.02 0.14 0.29 0.04 0.07 0.29 0.11 0.21 0.49 0.13
0.5 0.03 0.10 0.05 0.13 0.32 0.04 0.09 0.25 0.07 0.20 0.46 0.10
0.8 0.00 0.13 0.05 0.08 0.31 0.02 0.15 0.51 0.06 0.23 0.58 0.07
0.02 0.3 0.06 0.22 0.09 0.47 0.70 0.06 0.35 0.74 0.14 0.57 0.82 0.21
0.5 0.04 0.13 0.06 0.32 0.61 0.06 0.40 0.72 0.21 0.60 0.87 0.29
0.8 0.11 0.28 0.08 0.47 0.72 0.07 0.64 0.95 0.16 0.88 0.97 0.21
0.03 0.3 0.14 0.38 0.12 0.80 0.91 0.08 0.65 0.90 0.20 0.86 0.98 0.27
0.5 0.19 0.52 0.12 0.78 0.88 0.10 0.77 0.95 0.27 0.92 0.94 0.35
0.8 0.16 0.45 0.05 0.80 0.91 0.05 0.90 0.97 0.24 0.95 0.99 0.32
0.05 0.3 0.44 0.80 0.22 0.98 0.98 0.22 0.98 1.00 0.55 1.00 1.00 0.71
0.5 0.53 0.77 0.19 0.99 1.00 0.20 1.00 1.00 0.48 1.00 1.00 0.58
0.8 0.55 0.80 0.19 1.00 1.00 0.15 0.98 1.00 0.48 1.00 1.00 0.61
0.1 0.3 0.92 0.97 0.53 1.00 1.00 0.51 1.00 1.00 0.91 1.00 1.00 0.97
0.5 0.97 1.00 0.54 1.00 1.00 0.56 1.00 1.00 0.91 1.00 1.00 0.95
0.8 1.00 1.00 0.47 1.00 1.00 0.51 1.00 1.00 0.89 1.00 1.00 0.97
0.5 0.01 0.3 0.00 0.02 0.00 0.08 0.21 0.07 0.02 0.27 0.04 0.17 0.41 0.06
0.5 0.00 0.00 0.01 0.10 0.22 0.07 0.05 0.27 0.08 0.12 0.47 0.13
0.8 0.00 0.01 0.02 0.05 0.18 0.07 0.27 0.57 0.07 0.36 0.61 0.10
0.02 0.3 0.00 0.02 0.05 0.28 0.44 0.20 0.42 0.69 0.20 0.62 0.83 0.19
0.5 0.00 0.05 0.02 0.29 0.42 0.16 0.44 0.69 0.18 0.60 0.84 0.20
0.8 0.00 0.03 0.01 0.41 0.57 0.14 0.69 0.90 0.18 0.77 0.91 0.14
0.03 0.3 0.02 0.08 0.03 0.57 0.65 0.22 0.78 0.91 0.31 0.84 0.95 0.33
0.5 0.00 0.06 0.02 0.62 0.69 0.25 0.93 0.96 0.35 0.93 0.99 0.32
0.8 0.02 0.10 0.02 0.69 0.75 0.24 0.97 1.00 0.27 0.97 0.98 0.28
0.05 0.3 0.01 0.09 0.00 0.93 0.93 0.39 1.00 1.00 0.52 1.00 1.00 0.49
0.5 0.02 0.11 0.02 0.92 0.92 0.45 0.99 1.00 0.48 1.00 1.00 0.46
0.8 0.02 0.27 0.05 0.97 0.97 0.44 1.00 1.00 0.60 1.00 1.00 0.57
0.1 0.3 0.05 0.46 0.08 1.00 1.00 0.80 1.00 1.00 0.89 1.00 1.00 0.93
0.5 0.10 0.46 0.07 1.00 1.00 0.79 1.00 1.00 0.95 1.00 1.00 0.95
0.8 0.26 0.68 0.05 1.00 1.00 0.85 1.00 1.00 0.92 1.00 1.00 0.92
Results are based on 100 simulated datasets for each setting. As an aid to interpretation the powers§0:7 are indicated in bold. Abbreviations: Corr. =with main effects
correction, No C. =without main effects correction , F = FAM-MDR, F* = FAM-MDR*, PG= PGMDR.
doi:10.1371/journal.pone.0010304.t004
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[42] also used this idea in the context of rapid genomewide main
effects analysis. For multivariate traits and unrelated individuals,
similar principles of first removing trait correlations and then
submitting derived residuals to MB-MDR can be adopted. This is
work in progress and is particularly useful when measurements over
time are available. Exploiting the time-relatedness of phenotypic
measurements may in part compensate for the large sample sizes
needed to detect epistasis in genomic studies.
The Current implementation of FAM-MDR is not scalable to
GWAS. An efficient C++ implementation and a code version for
parallel analyses are on their way. First simulations indicate that
these enhancements will make GWAS feasible. For now, when
large-scale genomic screenings are performed with thousands of
markers, since FAM-MDR Part I is preparatory for subsequent
association analysis, FAM-MDR can include a pre-selection step of
good candidates of markers for epistasis analysis. These candidates
may be selected on the basis of information theoretic measures
[57,58] using information about the trait under investigation; or on
the basis of evidence from other data, i.e. using external and
independent information [59], e.g. omics analyses. Depending on
the strategy, an additional correction for data snooping in the pre-
screening step may be required to control type I error rates.
Also, a Part III can be added to a FAM-MDR analysis to
interpret the identified epistasis models. This is an important step
of the analysis and may or may not involve deriving good estimates
of the significant effects. Special care needs to be taken when
carrying out this step, in order not to be the victim of the so-called
‘‘winner’s curse’’ [60,61].
Currently, MB-MDR and FAM-MDR are based on Wald
statistics, whereas GMDR and PGMDRmake use of score statistics.
First, the score test is computationally more advantageous because it
only needs parameter estimates under the null whereas the Wald
test needs parameter estimates under the alternative and the
likelihood ratio test needs both. Second, even though the three tests
are asymptotically equivalent, the score test is the most powerful of
the three when the true parameter is close to the null value. In line
with the first release of an MB-MDR R package for unrelated
individuals, Wald statistics were implemented in the first version of
the FAM-MDR software. In the future, score statistics as well as
robust non-parametric statistics will be offered as additional options
in FAM-MDR. One of the major results that our simulation study
highlights is that PGMDR is too liberal in identifying epistasis
models. This is due to the inadequate correction for multiple testing,
implemented in the PGDMR software to date (Figure 2; Panel C).
In contrast, FAM-MDR correctly deals with multiple testing and
consequently leads to appropriate type I error rates (Figure 2; Panel
A). In effect, FAM-MDR is rather conservative, which is a property
inherited from the GRAMMAR approach it is built on. Indeed,
while first removing polygenic effects (FAM-MDR Part I), an over-
correction may take place, resulting in power loss and conservatism
to identify remaining genetic association signals. Improvements to
FAM-MDR that can remove this artifact are on the way. A second
result is that, generally speaking, FAM-MDR has optimal power
over PGMDR in virtual all considered simulation scenarios. In
addition, we have indicated that occasional better achieved
performance of PGMDR in terms of power is probably attributable
to sampling variability. Also note that when computing the
PGMDR power estimates in our simulation study, in case of a tie
we gave advantage to the model with the functional SNP pair.
A third important result is the influence of correcting for lower-
order effects when searching for significant epistatic interactions.
As was also pointed out by Calle et al. [40], MDR-like analysis
that does not account for important marginal effects is prone to
report false higher-order interactions, containing the significant
lower-order effects not accounted for. Although PGMDR
accommodates covariate adjustment, more work is needed to
enhance flexible implementation. FAM-MDR code is currently
available as an R-script, in which covariate adjustments are easily
incorporated in the model statement of the polygenic function.
More work is needed though to develop a genuine screening
strategy to search for optimal models, starting from important
main effects and ending with higher-order interaction models
beyond the two-way interactions considered in this work, with the
maximum order pre-defined by the user. This is future research,
since our simulations have shown that it is of utmost importance to
adjust for previous significant findings when moving to the search
space of interactions of the next order. Since the way lower-order
interactions are accounted for is part of a parametric paradigm,
the coding of these effects needs careful reflection. When lower-
order effects are important, a correction is warranted. When
lower-order effects are not important or not adequately coded,
over-adjusting for lower-order effects may lead to there being
virtually no variation left with which to identify higher-order
interactions. Hence, in reality the balance between necessary
corrections for important main effects and avoiding over-
correction needs to be considered to optimize the performance
of any epistasis detection method.
The current FAM-MDR implementation is only valid under the
assumption of no population structure, and our simulations
assume a homogeneous population. By using both between- and
within-family association – in contrast to PGMDR that uses only
within-family association – FAM-MDR gains power but this
comes at the price of sacrificing the built-in protection against
spurious results if population structure is present. A possible
solution to this problem lies in the use of Genomic Control [62].
Although PGMDR is a flexible tool to handle binary or
continuous outcome types, and accommodates covariate adjust-
ment, our application to real-life data has revealed some important
shortcomings that impact the power of a study. These include a
rather inefficient use of available information and the inability to
Table 5. Epistasis analyses of Amish Family Diabetes Study data.
Corr. No C.
Model P-value Model P-value
Orig. F (F*) rs2275703 in CASQ1; rs1501299 in APM1 0.619 (0.008) rs2275703 in CASQ1; rs1501299 in APM1 0.280 (0.005)
Split F (F*) rs2275703 in CASQ1; rs1501299 in APM1 0.070 (0.001) rs2275703 in CASQ1; rs1501299 in APM1 0.014 (,0.001)
Split PG rs2275703 in CASQ1; rs1028583 in HNF4A 0.059 rs1029629 in ADIPOR2; rs2425637 in HNF4A 0.303
Main effects corrections adjust the analyses for rs1884614 in HNF4A, rs2275703 and rs617698 in CASQ1, and rs1029629 in ADIPOR2. Abbreviations: Corr. =with main
effects correction, No C. =without main effects correction, Orig. = original data, Split = split pedigree, F = FAM-MDR, F* = FAM-MDR*, PG= PGMDR.
doi:10.1371/journal.pone.0010304.t005
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analyze complex and extended pedigrees with the present
PGMDR implementation.
Regarding missing genotypes, PGMDR discards families
entirely when data on one SNP are missing. Without minimizing
the need to also improve FAM-MDR’s handling of missing data
(whether at the genotype or phenotype level), not being able to
account for the full complexity of a pedigree is certainly a
drawback of PGMDR. We believe that methods that can
accommodate mixed study designs will become more and more
important due to the increasing practice of combining data from
different groups in consortia collaborations. FAM-MDR flexibly
deals with both unrelated and related individuals in the same
analysis whereas PGMDR excludes unrelated individuals, hereby
reducing the power of the association analysis.
Multi-generational pedigrees may provide more information on
inheritance patterns observed on genotype data, which improves
the quality of family-based tests of association. Due to limitations
of the PGMDR software, only FAM-MDR analysis was applied to
the extended pedigree data as such. With (or without) FAM-MDR
correction for main effects of rs1884614 in HNF4A, rs2275703 and
rs617698 in CASQ1, and rs1029629 in ADIPOR2, no evidence for a
significant interaction (or two-locus model) was found (Table 5).
Weak interactions between variations at these loci in contributing
to the log (GAUC) phenotype may still exist, but if so, FAM-
MDR was not able to identify them. In this context it is important
to note that FAM-MDR – like GRAMMAR – could be rather
conservative, especially for larger extended pedigrees [42]. On the
other hand, the (nearly) significant findings for the simplified
pedigree (Table 5) may potentially be false positive results driven
by both the artificial increase in sample size and by not
appropriately accounting for family structure. Indeed, McArdle
et al. [63] showed that the type I error of detecting SNP main
effects is elevated when family structure is ignored, and more
dramatically with increasing trait heritability, which may naturally
extend to (interactive) two-locus models as well. Lack of
appropriate accounting for multiple testing (PGMDR and FAM-
MDR*) may also increase the likelihood of observing spurious
associations. This is clearly seen for FAM-MDR* and to some
extent also for PGMDR (Table 5).
Improving the ability to detect gene-gene interactions in family
studies of complex disease may prove critical in identifying the
underlying sources of observed heritability. While it is apparent that
type 2 diabetes mellitus (T2DM) is polygenic, the genetic sources of
the observed heritability have yet to be completely identified [64],
and may include still unobserved gene-gene interactions. Detecting
interactions between genes associated with T2DM has thus far been
very challenging, due to a paucity of powerful statistical methods
and study datasets with adequate sample sizes [65]. Several studies
that have examined interactions between single variants in different
genes have shown mixed evidence of two-way interactions in
T2DM and T2DM-related traits like obesity and insulin resistance.
Using an approach which conditioned on linkage in one region to
identify evidence of linkage elsewhere, a linkage study of T2DM in
Mexican Americans from Starr County, Texas, identified the
interaction of genes on chromosomes 2 (CAPN10 (Calpain 10), then
NIDDM1) and 15 (near CYP19 (Cytochrome P450, family 19, or
Aromatase)) in contributiing to T2DM susceptibility [66]. Associ-
ation studies investigating interactions between variants of the Beta-
3 adrenergic receptor (ADRB3) and Uncoupling protein 1 (UCP1)
genes observed in weak [67] to no [68] effects on weight gain and
insulin resistance in Finnish and Danish populations, respectively. A
study of Type II iodothyronine deiodinase (DIO2) and ADRB3
polymorphisms showed a synergistic effect on an increased BMI,
suggesting an interaction between these two common gene variants
[69], while a study of intestinal fatty acid binding protein 2 (FABP2)
and ADRB3 showed no interaction on levels of fasting plasma
glucose or measures of insulin resistance [70]. In a study of
Mexican-American families participating in the population-based
San Antonio Family Heart Study [71], the combined presence of
common variants of Peroxisome proliferator-activated receptor
gamma (PPARc) and ADRB3 are correlated with significantly
higher BMI, insulin, and leptin levels than the presence of the
PPARc variants alone. Yet another study [72] examined two-locus
interactions among 23 loci in T2DM candidate genes in the risk of
T2DM, and found a significant interaction between variants in the
Uncoupling protein 1 (UCP2) and PPARc genes. Identification of
novel interactions and further confirmation of observed interactions
may be critical in characterizing the genetic risk factors for T2DM
and many other complex disease that remain among the
unidentified components of the heritability of these diseases, and
may have practical application in the identification of individuals
who may belong to groups at high risk of disease who can benefit
from preventive care.
In conclusion, FAM-MDR – unlike PGMDR – is able to handle
complex and large pedigrees with additional unrelated individuals.
In fact, FAM-MDR analysis on split pedigree data should not be
trusted because it might lead to overly optimistic results. On the
other hand, as pedigree size increases, the inherent conservative
nature of FAM-MDR could become more pronounced. Finally,
PGMDR results – and in fact also GMDR results – are too liberal as
no correction for multiple testing is carried out.
Supporting Information
Figure S1 Probability-probability plots for FAM-MDR analyses under
the null hypotheses of no association and no epistasis. The situation
considered is p= 0.5 and h2 = 0.3. Analyses are performed both
with and without correction for main effects. Results are based on
100 replicates. Panels A and B show results for data generated
under the null of no association, whereas panels C and D consider
data generated under the null hypothesis of no epistasis, for model
M27 and with g2 = 0.1. Panels A and C show results for analysis
with correction for main effects, panels B and D without.
Found at: doi:10.1371/journal.pone.0010304.s001 (0.50 MB TIF)
Figure S2 Additional power results for model M27, based on 100
replicates. Panels A and B show results for h2 = 0.5 and h2 = 0.8
respectively. Abbreviations: Corr. =with main effects correction,
No Corr. =without main effects correction.
Found at: doi:10.1371/journal.pone.0010304.s002 (1.54 MB TIF)
Figure S3 Additional power results for model M170, based on 100
replicates. Panels A and B show results for h2 = 0.5 and h2 = 0.8
respectively. Abbreviations: Corr. =with main effects correction,
No Corr. =without main effects correction.
Found at: doi:10.1371/journal.pone.0010304.s003 (1.53 MB TIF)
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